Research on the function and targeted therapy of BCL9 in malignant tumors
10.3760/cma.j.cn371439-20200224-00048
- VernacularTitle:恶性肿瘤中BCL9的功能及其靶向治疗研究
- Author:
Jingtong ZHAI
1
;
Fei MA
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院肿瘤内科 100021
- From:
Journal of International Oncology
2020;47(7):419-422
- CountryChina
- Language:Chinese
-
Abstract:
Canonical Wnt/β-catenin signaling pathway is of great significance to the occurrence and progression of tumors which make it an exciting target in cancer therapy. The pathway is also required in regeneration of normal tissues, so the specificity of inhibitors targeting this pathway may be affected. The coactivator of β-catenin, B cell lymphoma 9 (BCL9), is highly expressed merely in tumor cells. Accordingly, inhibitors targeting the interaction between β-catenin and BCL9 may demonstrate robust specificity and minimal toxicity. BCL9 increases tumor growth, invasion and metastasis by promoting epithelial-mesenchymal transition, up-regulating vascular endothelial growth factor and CD44 expression and regulating cancer stem cell traits. BCL9 promises to be a new target for cancer therapy.
